Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | SOD3 | P08294 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16221369 | 0.78 | PDCD1 (0.44) | PDCD1CD274SOD3HTR2AHTR2C | |
| SCHEMBL14930383 | 0.77 | PDCD1 (0.50) | PDCD1CD274SOD3HTR2AHTR2C | |
| SCHEMBL19042311 | 0.77 | PDCD1 (0.43) | PDCD1CD274SOD3HTR2AHTR2C | |
| SCHEMBL20912789 | 0.77 | PDCD1 (0.43) | PDCD1CD274SOD3HTR2AHTR2C | |
| SCHEMBL16220584 | 0.77 | PDCD1 (0.43) | PDCD1CD274SOD3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL23778209 | 0.76 | PDCD1 (0.43) | PDCD1CD274SOD3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL23779043 | 0.76 | PDCD1 (0.43) | PDCD1CD274SOD3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL23778179 | 0.76 | PDCD1 (0.43) | PDCD1CD274SOD3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL30756344 | 0.76 | PDCD1 (0.43) | PDCD1CD274SOD3HTR2AHTR2C | |
| SCHEMBL14925553 | 0.74 | PDCD1 (0.45) | PDCD1CD274SOD3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021127071-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | PDCD1 2334/4885CD274 3730/4885SOD3 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.